Press monitoring
A better way to read the genome
16.10.2015 | Press monitoring
UConn researchers have sequenced the RNA of the most complicated gene known in nature, using a hand-held sequencer no bigger than a cell phone. Genomicists from the UConn Institute of Systems Genomics teamed up with UK-based Oxford Nanopore Technologies to show that the company's MinION nanopore sequencer can sequence genes faster, better, and...
Medtronic CoreValve® Evolut® R System Demonstrates Exceptional Results at One Year
15.10.2015 | Press monitoring
DUBLIN and SAN FRANCISCO - October 14, 2015 - Medtronic plc (NYSE: MDT) announced new one-year data showing transcatheter aortic valve replacement (TAVR) with the CoreValve ® Evolut ® R System-the first and only next-generation recapturable, self-expanding valve available in the U.S.-led to exceptional clinical outcomes. ....
Medtronic Drug-Coated Balloon Sustains Superiority Over Balloon Angioplasty at Two Years in Patients with Peripheral Arterial Disease
15.10.2015 | Press monitoring
DUBLIN and SAN FRANCSICO - October 14, 2015 - Medtronic plc (NYSE: MDT) announced today that new two-year clinical data from the pivotal IN.PACT SFA Trial revealed that the IN.PACT ® Admiral ® drug-coated balloon (DCB) continues to provide superior clinical outcomes at two years compared to standard balloon angioplasty for the interventional...
REHACARE: Exoskeleton Therapy With Stroke and Traumatic Brain Injury
15.10.2015 | Press monitoring
DÜSSELDORF, Germany and LONDON, Oct. 15, 2015 (GLOBE NEWSWIRE) - On 17 th October, 3 pm Ekso Bionics will give a presentation on exoskeletons in neurological rehabilitation at the expert forum Marktplatz Gehirn at REHACARE exhibition (14.-17.October) in Düsseldorf. At the specialized exhibition area for patients with traumatic brain injury (hall...
Ablynx achieves first milestoner in immuno-oncology collaboration with Merck & CO., Inc.
15.10.2015 | Press monitoring
GHENT, Belgium, 15 October 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has achieved pre-clinical proof-of-concept with a Nanobody construct as part of its immuno-oncology collaboration with Merck & Co., Inc. ("Merck") [known as MSD outside the United States and Canada], triggering a €3.5 million milestone payment...
Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
15.10.2015 | Press monitoring
Basel, Switzerland, October 15, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the signing of an exclusive distribution and supply agreement with Hikma Pharmaceuticals LLC for Basilea's broad-spectrum antibiotic Zevtera ® (ceftobiprole medocaril) 1 for the Middle East and North Africa (MENA) region.
Galapagos advances triple combination therapy in cystic fibrosis
15.10.2015 | Press monitoring
Mechelen, Belgium; 15 October 2015: Galapagos NV (Euronext & NASDAQ: GLPG) announced today that GLPG2665 has been selected as the first next generation corrector compound candidate. Galapagos discovered multiple C2 corrector compound series, each with a different chemical scaffold and corresponding unique and complementary mode of action. ...
Medtronic CoreValve® System Shows Positive Clinical Outcomes in New Patient Populations
14.10.2015 | Press monitoring
New Data Show Low Mortality and Improved Quality of Life for Patients with Failed Surgical Aortic Valves, End-Stage Renal Disease and Low Gradient Aortic Stenosis. Medtronic plc (NYSE: MDT) today unveiled new clinical data that showed positive clinical outcomes at one year for the CoreValve System in new patient populations with significant...
Sharecare Wins Silver Stevie(R) in International Business Awards(SM)
14.10.2015 | Press monitoring
ATLANTA, Oct. 13, 2015 (GLOBE NEWSWIRE) - Sharecare, the leading online health and wellness engagement platform, today announced it is the recipient of a Silver Stevie® Award for Company of the Year in the Health Products and Services, and Pharmaceuticals category in the 12 th Annual International Business Awards. As the world's premier business...
Nabriva Therapeutics Hires Will Sargent as Vice President of Commercial Strategy and Investor Relations
14.10.2015 | Press monitoring
Vienna, Austria and King of Prussia, Pa., October 14, 2015 - Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced the appointment of Will Sargent as...
